Erasca, Inc. (ERAS)

Erasca, Inc. (ERAS) Healthcare & Pipeline Overview

Erasca, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates target non-small cell lung cancer, colorectal cancer, acute myeloid leukemia, advanced solid tumors, and recurrent glioblastoma multiforme, positioning them in the competitive oncology therapeutics market.

What Is the Investment Thesis for ERAS?

Erasca, Inc. presents a notable research candidate within the biotechnology sector, driven by its focus on RAS/MAPK pathway-driven cancers and its pipeline of targeted therapies. The company's lead candidates, including ERAS-007, ERAS-601, and ERAS-801, address significant unmet medical needs in oncology. Key value drivers include successful clinical trial outcomes, regulatory approvals, and potential commercialization of these therapies. The company's market capitalization stands at $5.91B as of 2026-05-04. Upcoming clinical trial data releases for ERAS-007 and ERAS-601 could serve as positive catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from other companies developing similar therapies. The company's beta of 1.05 indicates market correlation.

Based on FMP financials and quantitative analysis

ERAS Key Highlights

• Focus on RAS/MAPK pathway-driven cancers, a significant area of unmet medical need.
• Lead candidates ERAS-007, ERAS-601, and ERAS-801 target various cancers, diversifying the pipeline.
• Clinical-stage company with ongoing clinical trials, indicating progress towards potential commercialization.
• Market capitalization of $5.78B reflects investor confidence in the company's potential.
• Headquartered in San Diego, a hub for biotechnology innovation.

Who Are ERAS's Competitors?

ERAS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ERAS's Key Strengths?

• Focus on a specific and well-defined area of oncology (RAS/MAPK pathway).
• Promising pipeline of drug candidates in clinical development.
• Experienced management team with expertise in drug discovery and development.
• Strong intellectual property position.

What Are ERAS's Weaknesses?

• Clinical-stage company with no currently approved products.
• High cash burn rate associated with drug development.
• Reliance on successful clinical trial outcomes.
• Competition from larger pharmaceutical companies.

What Could Drive ERAS Stock Higher?

• Clinical trial data releases for ERAS-007 in non-small cell lung cancer.
• Clinical trial data releases for ERAS-601 in advanced or metastatic solid tumors.
• Enrollment of patients in ongoing clinical trials for ERAS-007, ERAS-601, and ERAS-801.
• Potential for strategic partnerships or collaborations to accelerate development.
• Regulatory submissions and potential approvals for lead drug candidates.

What Are the Key Risks for ERAS?

• Negative return on equity (-77.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays could negatively impact the company's pipeline.
• Regulatory hurdles and delays in the approval process could delay commercialization.
• Competition from other companies developing similar therapies could limit market share.
• High cash burn rate associated with drug development requires ongoing funding.
• Changes in the regulatory landscape could impact the company's business.

What Are the Growth Opportunities for ERAS?

• Expansion of ERAS-007 into additional cancer types: ERAS-007, currently in development for non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia, could be expanded to treat other cancers driven by ERK1/2. The global market for lung cancer therapeutics is projected to reach $38.9 billion by 2027. Successful expansion would significantly increase ERAS-007's market potential, providing a substantial growth opportunity for Erasca.
• Advancement of ERAS-601 through clinical trials: ERAS-601, an oral SHP2 inhibitor, is being developed for patients with advanced or metastatic solid tumors. Positive results from ongoing clinical trials could lead to regulatory approval and commercialization. The market for solid tumor therapies is estimated to be worth billions of dollars, offering a significant revenue opportunity for Erasca upon successful development and launch of ERAS-601.
• Development of ERAS-801 for recurrent glioblastoma multiforme: ERAS-801, a central nervous system-penetrant EGFR inhibitor, targets patients with recurrent glioblastoma multiforme. This specific focus addresses a critical unmet need in a difficult-to-treat cancer. The market for glioblastoma therapeutics is growing, and successful development of ERAS-801 could provide Erasca with a valuable niche product and a strong growth driver.
• Strategic partnerships and collaborations: Erasca could pursue strategic partnerships and collaborations with other pharmaceutical companies or research institutions to accelerate the development and commercialization of its pipeline. These partnerships could provide access to additional funding, expertise, and resources, enhancing Erasca's ability to bring its therapies to market more quickly and efficiently. The value of such partnerships can be significant, often involving upfront payments, milestone payments, and royalties on future sales.
• Expansion into new therapeutic areas: While currently focused on RAS/MAPK pathway-driven cancers, Erasca could expand its research and development efforts into other therapeutic areas within oncology. This diversification would broaden the company's pipeline and reduce its reliance on a single therapeutic pathway. The oncology market is vast and diverse, offering numerous opportunities for companies with innovative approaches to cancer treatment.

What Opportunities Does ERAS Have?

• Successful clinical trial results leading to regulatory approval.
• Expansion into new therapeutic areas within oncology.
• Strategic partnerships and collaborations with other companies.
• Potential for breakthrough therapies in difficult-to-treat cancers.

What Threats Does ERAS Face?

• Clinical trial failures or delays.
• Regulatory hurdles and delays in approval process.
• Competition from other companies developing similar therapies.
• Changes in the regulatory landscape.

What Are ERAS's Competitive Advantages?

• Proprietary drug candidates targeting specific cancer pathways.
• Strong intellectual property portfolio protecting its therapies.
• Experienced team of scientists and drug developers.
• Focus on a specific niche within the oncology market.

What Does ERAS Do?

Erasca, Inc., founded in 2018 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients suffering from RAS/MAPK pathway-driven cancers. Recognizing the significant unmet medical need in this area, Erasca is focused on creating targeted treatments that can improve patient outcomes. The company's approach involves discovering, developing, and ultimately commercializing novel therapies designed to address the underlying mechanisms of these cancers. Erasca's pipeline features several promising drug candidates, including ERAS-007, an oral inhibitor of ERK1/2, which is being developed for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia. ERAS-601, an oral SHP2 inhibitor, is another key candidate targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor, specifically for patients with recurrent glioblastoma multiforme. These candidates represent Erasca's commitment to addressing a range of cancers with significant therapeutic potential. With a team of experienced scientists and drug developers, Erasca is working to advance its pipeline through clinical trials and ultimately bring new treatment options to patients in need.

What Products and Services Does ERAS Offer?

• Discovers and develops therapies for RAS/MAPK pathway-driven cancers.
• Focuses on targeted treatments to improve patient outcomes in oncology.
• Develops oral inhibitors for various cancer types.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approval for its therapies from agencies like the FDA.
• Commercializes approved therapies to reach patients in need.

How Does ERAS Make Money?

• Develops and patents novel cancer therapies.
• Out-licenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through sales of approved therapies.
• Secures funding through venture capital, public offerings, and partnerships.

What Industry Does ERAS Operate In?

Erasca, Inc. operates within the biotechnology industry, specifically focusing on oncology therapeutics. The market for cancer therapies is substantial and growing, driven by an aging population and advancements in cancer research. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing targeted therapies. Erasca's focus on RAS/MAPK pathway-driven cancers positions it within a niche market with significant potential, as these pathways are implicated in a wide range of cancers. The biotechnology industry is characterized by high risk and high reward, with successful drug development leading to significant financial returns.

Who Are ERAS's Key Customers?

• Patients with RAS/MAPK pathway-driven cancers.
• Oncologists and other healthcare professionals who treat cancer patients.
• Hospitals and cancer centers that administer cancer therapies.
• Pharmaceutical companies that may partner with Erasca for commercialization.

Net buyingInsider Activity

Over the past six months, Erasca, Inc. insiders filed 10 SEC Form 4 transactions — 3 sales and 7 purchases. On net that is roughly 3.8M shares acquired (about $38.8M) — insiders putting money in tends to read as conviction.

ROE -77%Key Financial Metrics

Return on equity for Erasca, Inc. stands at -77.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -60.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.52 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

Erasca, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 46.27 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Erasca, Inc. revenue of about $7.5M for fiscal 2026, with EPS near $-0.96. The estimate reflects 5 contributing analysts.

ERAS Valuation & Market Position

With a $5.78B market cap, Erasca, Inc. sits in the mid-cap segment of the market. Relative to its peer group, ERAS's quantitative score of 71/100 is roughly in line with the peer average of 78/100.

ERAS Financials

ERAS Latest News

ERAS Analyst Consensus

ERAS MoonshotScore

Latest Erasca, Inc. Analysis

What Investors Ask About Erasca, Inc. (ERAS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources